Evidence map›Paper›PMID 29272495›Full record

ArticleInflammatory bowel diseases2017

Clinoptilolite in Dextran Sulphate Sodium-Induced Murine Colitis: Efficacy and Safety of a Microparticulate Preparation.

Stéphane Nizet, Eduardo Muñoz, Bernd L Fiebich, Peter M Abuja, Karl Kashofer, Kurt Zatloukal, Simone Tangermann, Lukas Kenner, Cornelius Tschegg, Dietmar Nagl and 4 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Inflammatory bowel diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Topically administered purified clinoptilolite-tuff for the treatment of cutaneous wounds: A prospective, randomised phase I clinical trial.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2022
    Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Stéphane NizetGLOCK Health, Science and Research GmbH, Deutsch-Wagram, Austria.
Eduardo MuñozMaimonides Biomedical Research Institute of Córdoba, Reina Sofía University Hospital, Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.
Bernd L FiebichVivaCell Biotechnology GmbH, Denzlingen, Germany.
Peter M AbujaInstitute of Pathology, Medical University of Graz, Graz, Austria.
Karl KashoferInstitute of Pathology, Medical University of Graz, Graz, Austria.
Kurt ZatloukalInstitute of Pathology, Medical University of Graz, Graz, Austria.
Simone TangermannDepartment of Experimental and Laboratory Animal Pathology, Medical University of Vienna, Austria.
Lukas KennerDepartment of Experimental and Laboratory Animal Pathology, Medical University of Vienna, Austria.
Cornelius TscheggGLOCK Health, Science and Research GmbH, Deutsch-Wagram, Austria.
Dietmar NaglGLOCK Health, Science and Research GmbH, Deutsch-Wagram, Austria.
Laurenz ScheichlGLOCK Health, Science and Research GmbH, Deutsch-Wagram, Austria.
Claudia Meisslitzer-RuppitschGLOCK Health, Science and Research GmbH, Deutsch-Wagram, Austria.
Michael FreissmuthInstitute of Pharmacology & Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center for Physiology and Pharmacology, Medical University Vienna, Vienna, Austria.
Thomas BergerGLOCK Health, Science and Research GmbH, Deutsch-Wagram, Austria.
Medical University of Graz · ATLudwig Boltzmann Institute for Cancer Research · ATMedical University of Vienna · ATUniversity of Córdoba · ES

Funding

Austrian Science Fund FWF P 26011
6 · The paper itself

Abstract

Background: Clinoptilolite is an aluminium silicate of natural origin; the microporous structure and the net negative charge of its crystal lattice allows for adsorption of ions, toxins, inflammatory mediators, and some microorganisms. We generated 2 preparations of purified clinoptilolite, which differed by about 10-fold in particle size, ie, a standard powder (GHC1) and a microparticulate fraction (GHC2) with a size of 3.6 µm and 0.39 µm (d50) respectively. These were examined for their ability to accelerate the recovery of mice from DSS (dextran sulphate sodium)-induced intestinal inflammation. Methods: Efficacy of clinoptilolite preparations was investigated by administering DSS-treated mice twice daily with 30 mg GHC2 or GHC1 for 5 consecutive days, followed by 5 days of recovery without DSS. To explore the safety of the microparticulate preparation (GHC2), mice were subjected to 4 cycles of DSS-exposure. We specifically verified that clinoptilolite microparticles were not systemically bioavailable by examining the gut tissue and the liver for the accumulation of microparticles by transmission electron microscopy. Results: Treatment of mice with GHC2 was superior to GHC1 and as effective as the reference compound 5-aminosalicylic acid in ameliorating the damage induced by the exposure to DSS. In addition, no clinoptilolite particle was observed in the intestinal epithelial layer, gut-associated lymph follicles, or in the liver. Conclusion: Our observations confirm that a microparticulate preparation of clinoptilolite is safe and effective in a murine model of inflammatory bowel disease and supports the hypothesis that the adsorptive capacity of clinoptilolite is of potential therapeutic relevance.

Indexed as

Disease Models, AnimalDrug CompoundingAnimalsColitisCytokinesDextran SulfateFecesFemaleGastrointestinal MicrobiomeInflammationIntestinal DiseasesMaleMiceMice, Inbred C57BLSafetyZeolitesclinoptiloliteCytokinesDextran SulfateZeolitescolitisDSSinflammationzeolite

Identifiers

PMID29272495
PMCPMC6176897
OpenAlexW2780218958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.